191 related articles for article (PubMed ID: 21962388)
21. Adalimumab: a review of its use in rheumatoid arthritis.
Bang LM; Keating GM
BioDrugs; 2004; 18(2):121-39. PubMed ID: 15046527
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.
Hochberg MC; Tracy JK; Hawkins-Holt M; Flores RH
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii13-6. PubMed ID: 14532140
[TBL] [Abstract][Full Text] [Related]
23. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
Keystone EC; van der Heijde D; Kavanaugh A; Kupper H; Liu S; Guérette B; Mozaffarian N
J Rheumatol; 2013 Sep; 40(9):1487-97. PubMed ID: 23818718
[TBL] [Abstract][Full Text] [Related]
24. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
[TBL] [Abstract][Full Text] [Related]
25. My treatment approach to rheumatoid arthritis.
Davis JM; Matteson EL; ;
Mayo Clin Proc; 2012 Jul; 87(7):659-73. PubMed ID: 22766086
[TBL] [Abstract][Full Text] [Related]
26. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
27. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A
J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
[TBL] [Abstract][Full Text] [Related]
28. Key findings towards optimising adalimumab treatment: the concentration-effect curve.
Pouw MF; Krieckaert CL; Nurmohamed MT; van der Kleij D; Aarden L; Rispens T; Wolbink G
Ann Rheum Dis; 2015 Mar; 74(3):513-8. PubMed ID: 24326008
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of rituximab on pulmonary nodulosis occurring or increasing in patients with rheumatoid arthritis during anti-TNF-α therapy.
De Stefano R; Frati E; Nargi F; Menza L
Clin Exp Rheumatol; 2011; 29(4):752-3. PubMed ID: 21906436
[No Abstract] [Full Text] [Related]
30. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate.
Torrance GW; Tugwell P; Amorosi S; Chartash E; Sengupta N
Rheumatology (Oxford); 2004 Jun; 43(6):712-8. PubMed ID: 15039494
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
Soubrier M; Puéchal X; Sibilia J; Mariette X; Meyer O; Combe B; Flipo RM; Mulleman D; Berenbaum F; Zarnitsky C; Schaeverbeke T; Fardellone P; Dougados M
Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
Spalding JR; Hay J
Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
35. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
36. Biological treatment in rheumatoid arthritis: when to stop?
Kirwan JR; Boers M
Lancet; 2014 Jan; 383(9914):288-9. PubMed ID: 24168959
[No Abstract] [Full Text] [Related]
37. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
Lovell DJ; Ruperto N; Goodman S; Reiff A; Jung L; Jarosova K; Nemcova D; Mouy R; Sandborg C; Bohnsack J; Elewaut D; Foeldvari I; Gerloni V; Rovensky J; Minden K; Vehe RK; Weiner LW; Horneff G; Huppertz HI; Olson NY; Medich JR; Carcereri-De-Prati R; McIlraith MJ; Giannini EH; Martini A; ;
N Engl J Med; 2008 Aug; 359(8):810-20. PubMed ID: 18716298
[TBL] [Abstract][Full Text] [Related]
39. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study.
Døhn UM; Ejbjerg B; Boonen A; Hetland ML; Hansen MS; Knudsen LS; Hansen A; Madsen OR; Hasselquist M; Møller JM; Ostergaard M
Ann Rheum Dis; 2011 Feb; 70(2):252-8. PubMed ID: 20980282
[TBL] [Abstract][Full Text] [Related]
40. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
Bukhari M; Abernethy R; Deighton C; Ding T; Hyrich K; Lunt M; Luqmani R; Kiely P; Bosworth A; Ledingham J; Ostör A; Gadsby K; McKenna F; Finney D; Dixey J;
Rheumatology (Oxford); 2011 Dec; 50(12):2311-3. PubMed ID: 21546351
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
